Biogen Inc. closed 51.05% below its 52-week high of $238.00, which the company reached on July 12th.

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target ...

Biogen has a 52 week low of $110.04 and a 52 week high of $238.00. The stock has a market cap of $17.36 billion, a P/E ratio of 10.60, a PEG ratio of 1.51 and a beta of 0.06.

Biogen Inc. (NASDAQ:BIIB – Free Report) – Analysts at Leerink Partnrs decreased their Q2 2025 earnings per share (EPS) estimates for Biogen in a research report issued on Sunday, April 13th.

Shares of Biogen Inc. BIIB shed 1.44% to $115.29 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

Recent rumours that Biogen was about to acquired by Samsung proved unfounded, but it turns out a deal has been in preparation. The South Korean firm just agreed to buy Biogen out of their ...

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

The European Commission has approved Eisai and Biogen's Leqembi in Alzheimer's disease. Kyowa Kirin has finished the build-out of a Japanese biologics plant. And more. The Trump administration has ...

2025 Future of Healthcategory EU authorizes Eisai-Biogen's drug for early Alzheimer's treatment April 16, 2025 Vietnam's trade ministry has issued a directive to crack down on illegal transhipment ...